Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Recursion Pharmaceuticals Inc shares valued at $76,926 were sold by Borgeson Blake on Oct 29 ’24. At $6.72 per share, Borgeson Blake sold 11,447 shares. The insider’s holdings dropped to 7,077,560 shares worth approximately $49.05 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Borgeson Blake purchased 11,447 shares, netting a total of over 76,926 in proceeds.
Before that, Marriott Tina had sold 6,000 shares from its account. In a trade valued at $37,855, the President and COO traded Recursion Pharmaceuticals Inc shares for $6.31 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $3.61 million.
As published in their initiating research note from Morgan Stanley on May 22, 2023, Recursion Pharmaceuticals Inc [RXRX] has been an Equal-weight and the price target has been revised to $8. Analysts at Needham started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March. As of September 16, 2022, KeyBanc Capital Markets has initiated its “an Overweight” rating for RXRX. Earlier on April 18, 2022, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for RXRX stock which previously was a “a Buy”.
Analyzing RXRX Stock Performance
During the last five days, there has been a surge of approximately 9.65%. Over the course of the year, Recursion Pharmaceuticals Inc shares have dropped approximately -29.72%. Shares of the company reached a 52-week high of $15.74 on 02/27/24 and a 52-week low of $5.89 on 09/04/24. A 50-day SMA is recorded $6.58, while a 200-day SMA reached $8.47. Nevertheless, trading volume fell to 5.75 million shares from 7.36 million shares the previous day.
Support And Resistance Levels for Recursion Pharmaceuticals Inc (RXRX)
According to the 24-hour chart, there is a support level at 6.71, which, if violated, would cause prices to drop to 6.49. In the upper region, resistance lies at 7.12. The next price resistance is at 7.31. RSI (Relative Strength Index) is 55.76 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.27, which suggests the price will decrease in the coming days. Percent R is at 17.88%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
